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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A336authorities to recommend that NSAIDs be prescribed at the lowest dose.
SoluMatrix diclofenac is approved for the management of mild to
moderate acute pain and osteoarthritis (OA) pain in adults. Based on
previous studies that examined the efﬁcacy and safety of SoluMatrix
diclofenac, we evaluated the pooled safety of SoluMatrix diclofenac in
older patients (65 years of age) across two phase 3 studies.
Methods: A 12-week randomized, multicenter, double-blind, parallel-
group study enrolled 305 chronic NSAID and/or acetaminophen users,
41 to 90 years of age with symptomatic and radiographically docu-
mented (Kellgren-Lawrence grade II or III) OA of the hip or knee.
Patients had baseline Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain subscale scores 40 mm at base-
line and a documented OA pain “ﬂare” (increase in WOMAC pain sub-
scale 15 mm) following NSAID/acetaminophen discontinuation.
Patients received either SoluMatrix diclofenac capsules 35 mg two or
three times daily (BID or TID) or placebo. A 12-month open-label,
multicenter study treated 601 chronic NSAID/acetaminophen users,
aged 40 to 86 years, with knee and/or hip OA. Patients initially received
SoluMatrix diclofenac 35-mg capsules BID; that could be increased to
TID and reduced as needed.
Results: Similar proportions of patients reported AEs in the 65 years
of age group (157/205 [76.6%]) compared with the <65 years of age
group (365/500 [73.0%]). In patients 65 years of age treated with
SoluMatrix diclofenac, the most commonly reported AEs included
nausea (18/205, 8.8%), diarrhea (17/205, 8.3%), and upper respiratory
tract infection (17/205, 8.3%). In patients <65 years of age treated with
SoluMatrix diclofenac, the most commonly reported AEs were head-
ache (40/500, 8.0%), upper respiratory tract infection (34/500, 6.8%),
and diarrhea (32/500, 6.4%). Forty-six of the 205 patients 65 years of
age (22.4%) withdrew from the study due to any AE, whereas 73/500
patients <65 years of age (14.6%) withdrew from the study due to an AE.
Few SoluMatrix diclofenac-treated patients experienced AEs reported
in class labeling for NSAIDs, including stroke, myocardial infarction,
gastrointestinal ulcers, perforation or hemorrhage, or liver function
abnormalities and occurred with no major differences among the two
age groups (Table). Two patients (<65 years of age) reportedmyocardial
infarctions, which were not considered to be treatment-related; there
were no deaths.Conclusions: In pooled 12-week and 12-month phase 3 studies, a
comparable proportion of SoluMatrix diclofenac-treated patients 65
years of age and <65 years of age experienced similar AEs. These data
add to the growing SoluMatrix diclofenac safety experience.
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BMI, PAIN AND FUNCTION IN PATIENTS WITH KNEE
OSTEOARTHRITIS
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Purpose: To evaluate the relationship between BMI and pain and
function in patients with knee osteoarthritis (KOA) undergoing multi-
professional clinical treatment.
Methods: Thirty-eight patients (four men and 34 women) aged 47-83
years old (mean 63.2 years) in usual treatment for knee OA for more
than three months, i.e. oral diacerhein and analgesics (according to
pain), orthotics (when indicated) were selected for a two-days two
months apart multiprofessional (medical, nutritional, psychological,
physical and occupational therapy, physical educator and social work-
ers) educational program on Ostearthritis. X-rays were performed to
classify the OA degree (Kelgreen & Lawrence e K&L). All patients were
evaluated at baseline (one month prior to ﬁrst class) and at 6 months (3
months after the second class) with height, weight (BMI estimation),
and asked to complete WOMAC, Lequesne, and visual analogue pain
scale questionnaires.
Results: Eight patients had grade I (K&L), eleven, grade II, thirteen,
grade III and six, grade IV. The results regarding change in VAS,
WOMAC-pain, WOMAC and Lequesne did not correlate to the initial
degree of osteoarthritis. There was no signiﬁcant BMI variation in this
study (average -0.2, SD¼ 0.22, range -4.9, 2.7). The higher the initial
BMI, the lower the improvement in pain (Spearman test, p ¼ 0.03). Pain
did not improve signiﬁcantly (p¼ 0.2). Function improved (p <0.001) in
inverse ratio to the initial BMI. However, the group that decreased BMI
tended to improve pain and function and the group that increased BMI
tended to improve pain and function (Kruskal-Wallis test, not
signiﬁcant).
Conclusions: BMI determines how patients will improve pain and
function.
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Purpose: To evaluate the correlations between common clinical OA
diagnostic tools in order to determine the value of each. A secondary
goal was to investigate the inﬂuence of gender differences on the
ﬁndings.
Methods: Five hundred and eighteen patients with knee OA were
evaluated using the Western Ontario and McMaster Osteoarthritis
Index (WOMAC) questionnaire, short form 36 (SF-36) Health Survey
and plain radiographs. Analysis of variance (ANOVA) was used to
compare the different domains of the WOMAC and SF-36 ques-
tionnaires between genders and the radiographic scale.
Results: Higher knee OA x-ray grade were associated with worse clin-
ical outcome: for womene higher scores for theWOMAC pain, function
and ﬁnal scores and lower scores in the SF-36 ﬁnal score; in men: lower
SF-36 overall and Physical domains scores. Gender differences were
found in all clinical scores that were tested, with women having worse
clinical scores for similar radiographic grading (p values< 0.001).
Conclusions: Knee radiographs for OA have an important role in the
clinical evaluation of the patient. Patients with higher levels of knee OA
in x-ray has a higher probability of having a worse clinical score in the
WOMAC and SF-36 scores. The gender differences suggest that for
similar knee OA x-ray grade women's clinical scores are lower.
